EP0650370A4 - Procedes et compositions permettant de cibler des tissus specifiques. - Google Patents
Procedes et compositions permettant de cibler des tissus specifiques.Info
- Publication number
- EP0650370A4 EP0650370A4 EP93914334A EP93914334A EP0650370A4 EP 0650370 A4 EP0650370 A4 EP 0650370A4 EP 93914334 A EP93914334 A EP 93914334A EP 93914334 A EP93914334 A EP 93914334A EP 0650370 A4 EP0650370 A4 EP 0650370A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compositions
- methods
- specific tissue
- targeting specific
- targeting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90609292A | 1992-06-08 | 1992-06-08 | |
US906092 | 1992-06-08 | ||
PCT/US1993/005260 WO1993025234A1 (fr) | 1992-06-08 | 1993-06-03 | Procedes et compositions permettant de cibler des tissus specifiques |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0650370A1 EP0650370A1 (fr) | 1995-05-03 |
EP0650370A4 true EP0650370A4 (fr) | 1995-11-22 |
Family
ID=25421920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP93914334A Withdrawn EP0650370A4 (fr) | 1992-06-08 | 1993-06-03 | Procedes et compositions permettant de cibler des tissus specifiques. |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0650370A4 (fr) |
JP (1) | JPH07507689A (fr) |
WO (1) | WO1993025234A1 (fr) |
Families Citing this family (259)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE263252T1 (de) | 1992-11-09 | 2004-04-15 | Us Health | Erzielbare vektorenpartikel |
GB9402857D0 (en) * | 1994-02-15 | 1994-04-06 | Isis Innovation | Targeting gene therapy |
US6150137A (en) | 1994-05-27 | 2000-11-21 | Ariad Pharmaceuticals, Inc. | Immunosuppressant target proteins |
GB9412844D0 (en) * | 1994-06-27 | 1994-08-17 | Medical Res Council | Improvements in or relating to therapeutic methods |
US6465253B1 (en) | 1994-09-08 | 2002-10-15 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US6127525A (en) * | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
US5770442A (en) | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
EP0840797B1 (fr) * | 1995-07-25 | 2014-09-03 | Crucell Holland B.V. | Procedes et moyens d'apport cible de genes |
GB9519776D0 (en) * | 1995-09-28 | 1995-11-29 | Casimir Colin | Materials and methods relating to the transfer of nucleic acid into stem cells |
WO1997024453A1 (fr) * | 1995-12-28 | 1997-07-10 | Chiron Corporation | Polypeptides chimeres de surface virale, specifiques d'un recepteur, pour l'incorporation et l'interiorisation d'une particule et d'un virus dans des cellules cibles |
DE19605279A1 (de) * | 1996-02-13 | 1997-08-14 | Hoechst Ag | Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung |
EP1860192A1 (fr) | 1996-09-17 | 2007-11-28 | Novartis Vaccines and Diagnostics, Inc. | Compositions et procédés de traitement de maladies intracellulaires |
US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
EP0973538B1 (fr) | 1997-04-10 | 2008-03-12 | University of Southern California | Proteines modifiees se fixant a des composants de matrice extracellulaires |
US6004798A (en) * | 1997-05-14 | 1999-12-21 | University Of Southern California | Retroviral envelopes having modified hypervariable polyproline regions |
US6162641A (en) * | 1997-06-06 | 2000-12-19 | The Regents Of The University Of Michigan | Neuregulin response element and uses therefor |
DE69838584T2 (de) | 1997-08-04 | 2008-06-26 | Cell Genesys, Inc., Foster City | Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung |
ATE374247T1 (de) | 1997-10-14 | 2007-10-15 | Darwin Molecular Corp | Thymidinkinase mutanten und fusionproteine mit thymidinkinase und guanylatekinase aktivitäten |
CN1263854C (zh) | 1997-11-06 | 2006-07-12 | 启龙股份公司 | 奈瑟球菌抗原 |
WO1999036544A2 (fr) | 1998-01-14 | 1999-07-22 | Chiron S.P.A. | Antigenes du $i(neisseria meningitidis) |
US7078483B2 (en) | 1998-04-29 | 2006-07-18 | University Of Southern California | Retroviral vectors including modified envelope escort proteins |
EP1645631B1 (fr) | 1998-05-01 | 2007-10-24 | Novartis Vaccines and Diagnostics, Inc. | Antigènes de Neisseria meningitidis et compositions |
EP0972841A1 (fr) * | 1998-05-20 | 2000-01-19 | Introgene B.V. | Présentation de protéines virales comme ligands de récepteur cellulaire de surface |
EP0959136A1 (fr) * | 1998-05-20 | 1999-11-24 | Introgene B.V. | Délivrance ciblée via un transporteur d' acides aminés cationiques |
EP0960942A3 (fr) * | 1998-05-20 | 2000-01-12 | Introgene B.V. | Délivrance ciblée via un transporteur d'acide aminé |
EP0959135A1 (fr) * | 1998-05-20 | 1999-11-24 | Introgene B.V. | Présentation de protéines virales et délivrance ciblée au récepteur cellulaire |
JP2002527066A (ja) | 1998-10-15 | 2002-08-27 | カイロン コーポレイション | 転移性乳癌および結腸癌調節遺伝子 |
US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
WO2000032773A1 (fr) | 1998-11-27 | 2000-06-08 | Darwin Discovery Ltd. | Compositions et methodes d'augmentation de la mineralisation de la substance osseuse |
ATE408695T1 (de) | 1998-12-16 | 2008-10-15 | Novartis Vaccines & Diagnostic | Menschliche cyclin-abhängige kinase (hpnqalre) |
US7063850B1 (en) | 1998-12-22 | 2006-06-20 | University Of Tennessee Research Foundation | Protective antigen of group A Streptococci |
US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
WO2000039302A2 (fr) | 1998-12-31 | 2000-07-06 | Chiron Corporation | Expression amelioree de polypeptides hiv et production de particules de type viral |
US6864235B1 (en) | 1999-04-01 | 2005-03-08 | Eva A. Turley | Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
US6911429B2 (en) | 1999-04-01 | 2005-06-28 | Transition Therapeutics Inc. | Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
WO2000066741A2 (fr) | 1999-04-30 | 2000-11-09 | Chiron S.P.A. | Antigenes de neisseria conserves |
GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
US7396905B1 (en) | 1999-05-21 | 2008-07-08 | Mckeon Frank | Calcipressins: endogenous inhibitors of calcineurin, uses and reagents related thereto |
GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
PT2275551E (pt) | 1999-10-29 | 2015-06-29 | Novartis Vaccines & Diagnostic | Péptidos antigénicos de neisseria |
JP2003516731A (ja) | 1999-11-18 | 2003-05-20 | カイロン コーポレイション | ヒトfgf−21遺伝子および遺伝子発現産物 |
US8168178B2 (en) | 1999-11-30 | 2012-05-01 | Curis, Inc. | Methods and compositions for regulating lymphocyte activity |
US6951839B1 (en) | 1999-11-30 | 2005-10-04 | Curis, Inc. | Methods and compositions for regulating lymphocyte activity |
MXPA02006962A (es) | 2000-01-17 | 2002-12-13 | Chiron Spa | Vacuna de vesicula de membrana exterior que comprende proteinas de membrana exterior de neisseria meningitidis serogrupo b. |
EP1854476A3 (fr) | 2000-02-09 | 2008-05-07 | Bas Medical, Inc. | Utilisation de la relaxine pour traiter des maladies associées à la vasoconstriction |
EP2075255A1 (fr) | 2000-03-08 | 2009-07-01 | Novartis Vaccines and Diagnostics, Inc. | Gène FGF-23 humain et produits d'expression de gènes |
EP1950297A2 (fr) | 2000-05-31 | 2008-07-30 | Novartis Vaccines and Diagnostics, Inc. | Compositions et procédés de traitement de maladie néoplastique utilisant la chimiothérapie et des sensibilisateurs à rayonnement |
US7700359B2 (en) | 2000-06-02 | 2010-04-20 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells |
EP1370684B1 (fr) | 2000-06-15 | 2008-05-28 | Novartis Vaccines and Diagnostics, Inc. | Polynucleotides lies au cancer du colon |
CA2881568C (fr) | 2000-10-27 | 2019-09-24 | Novartis Vaccines And Diagnostics, Inc. | Acides nucleiques et proteines derives des groupes de streptocoques a et b |
US7776523B2 (en) | 2000-12-07 | 2010-08-17 | Novartis Vaccines And Diagnostics, Inc. | Endogenous retroviruses up-regulated in prostate cancer |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
EP2706116A1 (fr) | 2001-01-17 | 2014-03-12 | Emergent Product Development Seattle, LLC | Proteines de fusion d'immunoglobuline de domaine de liaison |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
US7541512B2 (en) | 2001-03-30 | 2009-06-02 | Synageva Biopharma Corp. | Avians containing a lysozyme promoter transgene |
US7176300B2 (en) | 2001-03-30 | 2007-02-13 | Avigenics, Inc. | Avian lysozyme promoter |
EP1478751A4 (fr) | 2001-03-30 | 2005-10-19 | Avigenics Inc | Promoteur de lysozymes aviaires |
WO2002081641A2 (fr) | 2001-04-06 | 2002-10-17 | Georgetown University | Gene scc-112 et utilisations diagnostique et therapeutique de ce gene |
WO2002081639A2 (fr) | 2001-04-06 | 2002-10-17 | Georgetown University | Gene brcc2 et ses utilisations diagnostiques et therapeutiques |
AU2002258728A1 (en) | 2001-04-06 | 2002-10-21 | Georgetown University | Gene brcc-3 and diagnostic and therapeutic uses thereof |
JP4353701B2 (ja) | 2001-05-08 | 2009-10-28 | ダーウィン モレキュラー コーポレイション | Foxp3蛋白質を用いた霊長類における免疫機能の調節方法 |
JP5033303B2 (ja) | 2001-07-05 | 2012-09-26 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 抗原性c型hivポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用 |
EP2292772A1 (fr) | 2001-07-05 | 2011-03-09 | Novartis Vaccines and Diagnostics, Inc. | Vaccination VIH avec un ADN codant un polypeptide VIH et un polypeptide VIH |
US6867189B2 (en) | 2001-07-26 | 2005-03-15 | Genset S.A. | Use of adipsin/complement factor D in the treatment of metabolic related disorders |
US7550650B2 (en) | 2001-09-18 | 2009-06-23 | Synageva Biopharma Corp. | Production of a transgenic avian by cytoplasmic injection |
WO2003060143A2 (fr) | 2001-10-26 | 2003-07-24 | Id Biomedical Corporation Of Washington | Systeme d'expression de proteine efficace |
CA2465953A1 (fr) | 2001-11-09 | 2003-05-15 | Georgetown University | Nouveaux isoformes de l'inhibiteur de la croissance de cellules endotheliales vasculaires |
US7335761B2 (en) | 2001-11-30 | 2008-02-26 | Avigenics, Inc. | Avian gene expression controlling regions |
US6875588B2 (en) | 2001-11-30 | 2005-04-05 | Avigenics, Inc. | Ovomucoid promoter and methods of use |
US7294507B2 (en) | 2001-11-30 | 2007-11-13 | Avigenics, Inc. | Ovomucoid promoters and methods of use |
EP2335724A1 (fr) | 2001-12-12 | 2011-06-22 | Novartis Vaccines and Diagnostics S.r.l. | Immunisation contre la Chlamydia trachomatis |
SG148035A1 (en) | 2002-01-08 | 2008-12-31 | Novartis Vaccines & Diagnostic | Gene products differentially expressed in cancerous breast cells and their methods of use |
US7135562B2 (en) | 2002-03-14 | 2006-11-14 | University Of Cincinnati | Avian iFABP gene expression controlling region |
CN100593544C (zh) | 2002-03-15 | 2010-03-10 | 惠氏控股有限公司 | 酶活性减少的非典型流感嗜血杆菌的p4蛋白突变体 |
JP2005520543A (ja) | 2002-03-21 | 2005-07-14 | サイグレス ディスカバリー, インコーポレイテッド | 癌における新規組成物および方法 |
US7244565B2 (en) | 2002-04-10 | 2007-07-17 | Georgetown University | Gene shinc-3 and diagnostic and therapeutic uses thereof |
AU2003276679A1 (en) | 2002-06-13 | 2003-12-31 | Chiron Corporation | Vectors for expression of hml-2 polypeptides |
CA2421269A1 (fr) | 2002-08-09 | 2004-02-09 | President And Fellows Of Harvard College | Methodes et compositions pour prolonger la duree de vie et accroitre la resistance au stress de cellules et d'organismes |
UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
EP1575517B1 (fr) | 2002-12-24 | 2012-04-11 | Rinat Neuroscience Corp. | Anticorps anti-ngf et procedes d'utilisation de ces anticorps |
WO2004074321A2 (fr) | 2003-02-14 | 2004-09-02 | Sagres Discovery, Inc. | Nouveaux cibles therapeutiques du recepteur de couplage a la proteine g dans le cancer |
US7767387B2 (en) | 2003-06-13 | 2010-08-03 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
US20040170982A1 (en) | 2003-02-14 | 2004-09-02 | Morris David W. | Novel therapeutic targets in cancer |
DE602004030535D1 (de) | 2003-02-19 | 2011-01-27 | Rinat Neuroscience Corp | Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor-antagonisten und eines nsaid und diese enthaltende zusammensetzung |
GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
ATE513471T1 (de) | 2003-04-21 | 2011-07-15 | Epeius Biotechnologies Corp | Verfahren und zusammensetzungen zur behandlung von erkrankungen |
US20070178066A1 (en) | 2003-04-21 | 2007-08-02 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
US20060025337A1 (en) | 2003-07-01 | 2006-02-02 | President And Fellows Of Harvard College | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases |
US9532994B2 (en) | 2003-08-29 | 2017-01-03 | The Regents Of The University Of California | Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins |
WO2005062955A2 (fr) | 2003-12-23 | 2005-07-14 | Rinat Neuroscience Corp. | Anticorps anti-trkc agonistes et procedes d'utilisation |
KR101222281B1 (ko) | 2004-03-29 | 2013-01-28 | 가르파마 컴퍼니 리미티드 | 신규 갈렉틴 9 개변체 단백질 및 그 용도 |
ES2338344T3 (es) | 2004-04-07 | 2010-05-06 | Rinat Neuroscience Corporation | Procedimiento de tratamiento del dolor de cancer de hueso mediante la administracion de una antagonista del factor de crecimiento neuronal. |
US7875275B2 (en) | 2004-06-16 | 2011-01-25 | The General Hospital Corporation | Use of Bridge-1 and activators and inhibitors thereof in the treatment of insulin deficiency and diabetes |
EP1789593B1 (fr) | 2004-07-09 | 2017-03-15 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Formes solubles de glycoproteine g des virus hendra |
EP1773375A1 (fr) | 2004-07-14 | 2007-04-18 | University of Utah Research Foundation | Compositions et utilisations liees a des netrines |
US20060024677A1 (en) | 2004-07-20 | 2006-02-02 | Morris David W | Novel therapeutic targets in cancer |
US7807165B2 (en) | 2004-07-30 | 2010-10-05 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
ES2385045T3 (es) | 2005-02-18 | 2012-07-17 | Novartis Vaccines And Diagnostics, Inc. | Inmunógenos de Escherichia coli uropatogénica |
EP1865981A2 (fr) | 2005-04-07 | 2007-12-19 | Chiron Corporation | Cacna1e dans le diagnostic, la detection et le traitement du cancer |
US20090220495A1 (en) | 2005-04-07 | 2009-09-03 | Abdallah Fanidi | Cancer Related Genes (PRLR) |
CA2615615A1 (fr) | 2005-07-22 | 2007-02-01 | Y's Therapeutics Co., Ltd. | Anticorps anti-cd26 et methodes d'utilisation de ces derniers |
ES2460517T3 (es) | 2005-07-25 | 2014-05-13 | Emergent Product Development Seattle, Llc | Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20 |
AP2008004467A0 (en) | 2005-11-14 | 2008-06-30 | Rinat Neurosciene Corp | Antagonist antibodies directed against calcitonin generelated peptide anf methods using same |
US7935342B2 (en) | 2006-02-02 | 2011-05-03 | Rinat Neuroscience Corp. | Methods for treating obesity by administering a trkB antagonist |
EP1993558B1 (fr) | 2006-02-27 | 2014-07-30 | The Regents of The University of California | Composés oxystérols et hedgehog voie |
RU2461572C2 (ru) | 2006-06-07 | 2012-09-20 | Биоэллаенс К.В. | Антитела, распознающие содержащий углеводы эпитоп на cd-43 и сеа, экспрессируемых на злокачественных клетках, и способы их применения |
EP2035035A2 (fr) | 2006-06-09 | 2009-03-18 | Novartis AG | Compositions immunogenes pour streptococcus agalactiae |
AU2007257692B2 (en) | 2006-06-12 | 2013-11-14 | Aptevo Research And Development Llc | Single-chain multivalent binding proteins with effector function |
JP2010500399A (ja) | 2006-08-16 | 2010-01-07 | ノバルティス アーゲー | 尿路病原性大腸菌由来の免疫原 |
PL2484375T3 (pl) | 2006-09-26 | 2018-09-28 | Infectious Disease Research Institute | Kompozycja szczepionki zawierająca syntetyczny adiuwant |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
EP2629094A1 (fr) | 2007-01-24 | 2013-08-21 | Carnegie Mellon University | Biocapteurs optiques |
WO2008116116A2 (fr) | 2007-03-20 | 2008-09-25 | Harold Brem | Compositions gm-csf cosméceuticales et leurs procédés d'utilisation |
EP2155777A2 (fr) | 2007-04-10 | 2010-02-24 | The Administrators of the Tulane Educational Fund | Formes solubles et ancrées sur membrane de protéines de sous-unité du virus lassa |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
US9526737B2 (en) | 2007-12-03 | 2016-12-27 | The Regents Of The University Of California | Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling |
CN102216329A (zh) | 2007-12-17 | 2011-10-12 | 辉瑞有限公司 | 间质性膀胱炎的治疗 |
EP2245063B1 (fr) | 2007-12-18 | 2015-08-26 | BioAlliance C.V. | Anticorps reconnaissant un épitope contenant des glucides sur cd-43 et cea exprimés sur des cellules cancéreuses et leurs procédés d'utilisation |
WO2009126306A2 (fr) | 2008-04-10 | 2009-10-15 | Cell Signaling Technology, Inc. | Compositions et procédés pour la détection des mutations d’egfr en cas de cancer |
DK2132228T3 (da) | 2008-04-11 | 2011-10-10 | Emergent Product Dev Seattle | CD37-immunterapeutisk middel og kombination med bifunktionelt kemoterapeutisk middel deraf |
US7928189B2 (en) | 2008-05-05 | 2011-04-19 | Ottawa Health Research Institute | PCSK9 polypeptide fragment |
WO2009150623A1 (fr) | 2008-06-13 | 2009-12-17 | Pfizer Inc | Traitement de la prostatite chronique |
TWI516501B (zh) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9拮抗劑類 |
WO2010039536A2 (fr) | 2008-09-23 | 2010-04-08 | President And Fellows Of Harvard College | Sirt4 et utilisations de celui-ci |
WO2010080985A1 (fr) | 2009-01-08 | 2010-07-15 | Dana-Farber Cancer Institute, Inc. | Compositions et procédés pour induire la différenciation du tissu adipeux brun |
JP2012515532A (ja) | 2009-01-20 | 2012-07-12 | ラモット アット テル アビブ ユニバーシティ, リミテッド | Mir−21プロモーター駆動性標的がん治療 |
US9719069B2 (en) | 2009-01-27 | 2017-08-01 | University Of Utah Research Foundation | Methods and compositions relating to viral latency |
WO2010086828A2 (fr) | 2009-02-02 | 2010-08-05 | Rinat Neuroscience Corporation | Anticorps monoclonaux agonistes anti-trkb |
EP2403526B1 (fr) | 2009-03-06 | 2019-05-15 | GlaxoSmithKline Biologicals SA | Antigènes de chlamydia |
CA2755870C (fr) | 2009-03-20 | 2019-04-09 | Angioblast Systems, Inc. | Production de cellules pluripotentes reprogrammees |
WO2010118243A2 (fr) | 2009-04-08 | 2010-10-14 | Genentech, Inc. | Utilisation d'antagonistes de il-27 pour traiter le lupus |
BRPI1013780B8 (pt) | 2009-04-14 | 2022-10-04 | Novartis Ag | Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica |
WO2010124365A1 (fr) | 2009-04-27 | 2010-11-04 | Ottawa Hospital Research Institute | Compositions et méthodes permettant de moduler les cellules souches et leurs utilisations |
TWI549688B (zh) | 2009-06-05 | 2016-09-21 | 美國疾病傳染研究機構 | 合成的葡萄吡喃糖基脂質佐劑 |
WO2010146511A1 (fr) | 2009-06-17 | 2010-12-23 | Pfizer Limited | Traitement d'une vessie hyperactive |
PL2464658T3 (pl) | 2009-07-16 | 2015-03-31 | Novartis Ag | Immunogeny z Escherichia coli o zniesionej toksyczności |
US8563261B2 (en) | 2009-09-28 | 2013-10-22 | The Trustees Of The University Of Pennsylvania | Method of diagnosing and treating interstitial cystitis |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
JP2013517772A (ja) | 2010-01-21 | 2013-05-20 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 遺伝子発見および標的確認を補助するための状況特異的遺伝子スクリーニングプラットフォーム |
TWI552760B (zh) | 2010-02-24 | 2016-10-11 | 雷那特神經科學股份有限公司 | 拮抗劑抗-il-7受體抗體及方法 |
GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
CN102844332B (zh) | 2010-03-11 | 2015-08-19 | 瑞纳神经科学公司 | 呈pH依赖性抗原结合的抗体 |
GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
WO2011133931A1 (fr) | 2010-04-22 | 2011-10-27 | Genentech, Inc. | Utilisation d'antagonistes d'il-27 pour traiter une maladie intestinale inflammatoire |
WO2012015758A2 (fr) | 2010-07-30 | 2012-02-02 | Saint Louis University | Méthodes de traitement de la douleur |
US9539427B2 (en) | 2010-11-08 | 2017-01-10 | The Johns Hopkins University | Methods for improving heart function |
WO2012075243A2 (fr) | 2010-12-01 | 2012-06-07 | The University Of North Carolina At Chapel Hill | Procédés et compositions destinés à cibler des sites de croissance néovasculaire |
WO2012072769A1 (fr) | 2010-12-01 | 2012-06-07 | Novartis Ag | Epitopes rrgb de pneumocoque et combinaisons de variantes |
EP3026432A3 (fr) | 2010-12-27 | 2016-07-27 | Brown University | Procédé de prévision de la réponse du patient au traitement avec biglycan |
EA027236B1 (ru) | 2011-04-08 | 2017-07-31 | Иммьюн Дизайн Корп. | Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа |
US20130071375A1 (en) | 2011-08-22 | 2013-03-21 | Saint Louis University | Compositions and methods for treating inflammation |
WO2013028527A1 (fr) | 2011-08-23 | 2013-02-28 | Indiana University Research And Technology Corporation | Compositions et procédés pour traiter le cancer |
US10093705B2 (en) | 2011-09-13 | 2018-10-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for brown fat induction and activity using FNDC5 |
US10378060B2 (en) | 2011-10-14 | 2019-08-13 | Dana-Farber Cancer Institute, Inc. | ZNF365/ZFP365 biomarker predictive of anti-cancer response |
CN104053672A (zh) | 2011-11-11 | 2014-09-17 | 瑞纳神经科学公司 | Trop-2特异性抗体及其用途 |
RU2014123030A (ru) | 2011-12-22 | 2016-02-20 | Ринат Ньюросайенс Корп. | Антагонистические антитела против человеческого рецептора гормона роста и способы их применения |
WO2013093693A1 (fr) | 2011-12-22 | 2013-06-27 | Rinat Neuroscience Corp. | Anticorps spécifiques de staphylococcus aureus et leurs utilisations |
HUE044841T2 (hu) | 2012-02-07 | 2019-11-28 | Infectious Disease Res Inst | TLR4 agonistákat tartalmazó javított adjuváns készítmények és azok alkalmazási eljárásai |
WO2013164754A2 (fr) | 2012-05-04 | 2013-11-07 | Pfizer Inc. | Régimes immunothérapeutiques basés sur des antigènes associés à la prostate et un vaccin |
WO2013169399A1 (fr) | 2012-05-07 | 2013-11-14 | The Regents Of The University Of California | Oxy133, un analogue de l'oxystérol, induisant l'ostéo-genèse et la signalisation hedgehog et inhibant l'adipogenèse |
SI2850431T1 (en) | 2012-05-16 | 2018-08-31 | Immune Design Corp. | Vaccine against HSV-2 |
US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
BR112015010722A2 (pt) | 2012-11-09 | 2017-08-22 | Pfizer | Anticorpos específicos de fator de crescimento derivado de plaquetas de isoforma b e composições e usos dos mesmos |
AU2014236086B2 (en) | 2013-03-14 | 2020-03-05 | Genvivo, Inc. | Improved thymidine kinase gene |
CA2906624A1 (fr) | 2013-03-15 | 2014-09-25 | Dyax Corp. | Anticorps anti-kallicreine plasmatique |
JP6426706B2 (ja) | 2013-04-18 | 2018-11-21 | イミューン デザイン コーポレイション | がん処置で使用するためのgla単剤療法 |
WO2014179756A1 (fr) | 2013-05-02 | 2014-11-06 | The Regents Of The University Of California | Agents de ciblage osseux à base d'oxystérol ostéogène à sélectivité osseuse |
JP2016520058A (ja) | 2013-05-07 | 2016-07-11 | ライナット ニューロサイエンス コーポレイション | 抗グルカゴン受容体抗体およびその使用方法 |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
EP3008043A2 (fr) | 2013-06-14 | 2016-04-20 | University Of Utah Research Foundation | Analogues triazol-1-ol médicaments de latence antirétroviral |
WO2015006641A2 (fr) | 2013-07-12 | 2015-01-15 | Georgia State University Research Foundation, Inc. | Procédés et compositions d'interférence pour polymérase d'adn et synthèse d'adn |
US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
BR112016002008B1 (pt) | 2013-08-02 | 2021-06-22 | Pfizer Inc. | Anticorpos anti-cxcr4, seu uso, conjugado anticorpo-fármaco e composição farmacêutica |
US9683998B2 (en) | 2013-11-13 | 2017-06-20 | Pfizer Inc. | Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof |
WO2015087187A1 (fr) | 2013-12-10 | 2015-06-18 | Rinat Neuroscience Corp. | Anticorps anti-sclérostine |
WO2015109212A1 (fr) | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anticorps anti-il-2 et compositions et utilisations de ceux-ci |
MX2016012188A (es) | 2014-03-21 | 2017-04-27 | Teva Pharmaceuticals Int Gmbh | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos. |
WO2015164743A2 (fr) | 2014-04-24 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Suppresseur de tumeur et biomarqueurs oncogènes prédictifs de réponse à un inhibiteur de point de contrôle anti-immunitaire |
WO2015168474A1 (fr) | 2014-04-30 | 2015-11-05 | President And Fellows Of Harvard College | Protéines de fusion pour le traitement du cancer et procédés associés |
EP3143138B1 (fr) | 2014-05-13 | 2022-03-23 | BioAtla, Inc. | Protéines biologiques conditionnellement actives |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
EP3186284B1 (fr) | 2014-08-28 | 2022-04-06 | BioAtla, Inc. | Récepteurs d'antigènes chimères conditionnellement actifs pour cellules t modifiées |
US11111288B2 (en) | 2014-08-28 | 2021-09-07 | Bioatla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
KR20170044115A (ko) | 2014-09-03 | 2017-04-24 | 바이오아트라, 엘엘씨 | 동일한 진핵생물 세포 생산 숙주 내 조건부 활성 생체 단백질의 발견 및 제조 |
US20180133252A9 (en) | 2014-09-09 | 2018-05-17 | Unum Therapeutics Inc. | Chimeric receptors and uses thereof in immune therapy |
CA2963091A1 (fr) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Biomarqueurs a base d'angiopoietine -2 utilises pour la prediction de la reponse de point de controle anti-immunitaire |
CN113230384A (zh) | 2014-10-09 | 2021-08-10 | 丹娜法伯癌症研究院 | 用于治疗免疫失调的多次-可变il-2剂量方案 |
TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
US10948492B2 (en) | 2015-03-06 | 2021-03-16 | Dana-Farber Cancer Institute, Inc. | PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers |
EP3735982A1 (fr) | 2015-03-10 | 2020-11-11 | The University of Massachusetts | Ciblage de gdf6 et de la signalisation médiée par les bmp pour une thérapie contre le mélanome |
US9758575B2 (en) | 2015-04-06 | 2017-09-12 | Yung Shin Pharmaceutical Industrial Co. Ltd. | Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof |
MY196625A (en) | 2015-04-13 | 2023-04-23 | Pfizer | Therapeutic Antibodies and Their Uses |
CA2993026A1 (fr) | 2015-07-21 | 2017-01-26 | Dyax Corp. | Inhibiteur d'anticorps monoclonal du facteur xiia |
WO2017015334A1 (fr) | 2015-07-21 | 2017-01-26 | Saint Louis University | Compositions et méthodes pour diagnostiquer et traiter l'infertilité associée à l'endométriose |
EP3325010B1 (fr) | 2015-07-23 | 2023-06-21 | The Regents of The University of California | Anticorps anti-facteur de coagulation xia et leurs utilisations |
NZ739871A (en) | 2015-08-19 | 2022-05-27 | Pfizer | Tissue factor pathway inhibitor antibodies and uses thereof |
CN113896789A (zh) | 2015-09-15 | 2022-01-07 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其用途 |
UA126278C2 (uk) | 2015-09-21 | 2022-09-14 | Аптево Рісьорч Енд Девелопмент Ллс | Поліпептиди, які зв'язують cd3 |
US11207393B2 (en) | 2015-10-16 | 2021-12-28 | President And Fellows Of Harvard College | Regulatory T cell PD-1 modulation for regulating T cell effector immune responses |
CA3001859A1 (fr) | 2015-10-16 | 2017-04-20 | The Trustees Of Columbia University In The City Of New York | Compositions et methodes d'inhibition d'antigenes specifiques a une lignee |
CA2946113A1 (fr) | 2015-10-23 | 2017-04-23 | Pfizer Inc. | Anticorps anti-il-2 et leurs compositions et methodes d'utilisation |
WO2017075037A1 (fr) | 2015-10-27 | 2017-05-04 | Scholar Rock, Inc. | Facteurs de croissance amorcés et leurs utilisations |
US20210106661A1 (en) | 2015-10-29 | 2021-04-15 | Dana-Farber Cancer Institute, Inc. | Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids |
CN106699889A (zh) | 2015-11-18 | 2017-05-24 | 礼进生物医药科技(上海)有限公司 | 抗pd-1抗体及其治疗用途 |
RU2744860C2 (ru) | 2015-12-30 | 2021-03-16 | Кодиак Сайенсиз Инк. | Антитела и их конъюгаты |
TW201936640A (zh) | 2016-01-21 | 2019-09-16 | 美商輝瑞股份有限公司 | 對表皮生長因子受體變異體iii具特異性之抗體類及彼等之用途 |
AU2017238054B2 (en) | 2016-03-21 | 2023-10-19 | Dana-Farber Cancer Institute, Inc. | T-cell exhaustion state-specific gene expression regulators and uses thereof |
ES2930255T3 (es) | 2016-05-13 | 2022-12-09 | Bioatla Inc | Anticuerpos anti-Ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos |
EP3458475B1 (fr) | 2016-05-16 | 2022-07-27 | Access to Advanced Health Institute | Formulation contenant un agoniste de tlr et procédés d'utilisation |
KR102472026B1 (ko) | 2016-06-01 | 2022-11-30 | 액세스 투 어드밴스드 헬스 인스티튜트 | 사이징제를 함유하는 나노명반 입자 |
JP7099967B2 (ja) | 2016-07-01 | 2022-07-12 | リサーチ ディベロップメント ファウンデーション | 幹細胞由来移植片からの増殖性細胞の排除 |
WO2018057618A1 (fr) | 2016-09-20 | 2018-03-29 | Dana-Farber Cancer Institute, Inc. | Compositions et méthodes pour l'identification, l'évaluation, la prévention et le traitement de la lma au moyen de biomarqueurs usp10 et de modulateurs |
US20180119141A1 (en) | 2016-10-28 | 2018-05-03 | Massachusetts Institute Of Technology | Crispr/cas global regulator screening platform |
US20190345501A1 (en) | 2017-02-07 | 2019-11-14 | Massachusetts Institute Of Technology | Methods and compositions for rna-guided genetic circuits |
KR20190124753A (ko) | 2017-03-03 | 2019-11-05 | 리나트 뉴로사이언스 코프. | 항-gitr 항체 및 이의 사용 방법 |
JP7177076B2 (ja) | 2017-03-16 | 2022-11-22 | ファイザー・インク | チロシン原栄養性 |
CA3059938A1 (fr) | 2017-04-14 | 2018-10-18 | Kodiak Sciences Inc. | Anticorps antagonistes du facteur d du complement et leurs conjugues |
WO2018220584A1 (fr) | 2017-06-02 | 2018-12-06 | Pfizer Inc. | Anticorps spécifiques à la flt3 et leurs utilisations |
EP3634496A4 (fr) | 2017-06-06 | 2021-09-08 | Dana-Farber Cancer Institute, Inc. | Procédés de sensibilisation de cellules cancéreuses à une destruction médiée par des lymphocytes t par modulation de voies moléculaires |
JP7034183B2 (ja) | 2017-06-13 | 2022-03-11 | ボストンジーン コーポレイション | 免疫チェックポイント遮断療法に対するレスポンダー及び非レスポンダーを特定するためのシステム及び方法 |
WO2019016784A1 (fr) | 2017-07-21 | 2019-01-24 | Universidade De Coimbra | Anticorps anti-nucléoline |
EP3692370A2 (fr) | 2017-10-04 | 2020-08-12 | OPKO Pharmaceuticals, LLC | Articles et procédés destinés à la thérapie personnalisée du cancer |
CN112020518A (zh) | 2018-02-01 | 2020-12-01 | 辉瑞公司 | 靶向cd70的嵌合抗原受体 |
US11377500B2 (en) | 2018-02-01 | 2022-07-05 | Pfizer Inc. | Antibodies specific for CD70 and their uses |
KR20200128116A (ko) | 2018-02-28 | 2020-11-11 | 화이자 인코포레이티드 | Il-15 변이체 및 이의 용도 |
MX2020012539A (es) | 2018-05-23 | 2021-02-16 | Pfizer | Anticuerpos especificos para cd3 y sus usos. |
MX2020012607A (es) | 2018-05-23 | 2021-01-29 | Pfizer | Anticuerpos especificos para gucy2c y sus usos. |
KR20220036908A (ko) | 2018-08-28 | 2022-03-23 | 보르 바이오파마 인크. | 유전자 조작된 조혈 줄기 세포 및 그의 용도 |
EP3721896B1 (fr) | 2019-04-08 | 2023-11-29 | Giuseppe Scalabrino | Facteur de croissance épidermique (egf) et ses variantes pour le traitement ou la prévention de troubles inflammatoires de demyelinisation |
US20210005284A1 (en) | 2019-07-03 | 2021-01-07 | Bostongene Corporation | Techniques for nucleic acid data quality control |
AU2020363372A1 (en) | 2019-10-07 | 2022-05-19 | University Of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
CA3152623A1 (fr) | 2019-10-11 | 2021-04-15 | Richard D. Cummings | Anticorps anti-tn et leurs utilisations |
US20230067811A1 (en) | 2020-01-24 | 2023-03-02 | University Of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
WO2021205325A1 (fr) | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Anticorps anti-gucy2c et leurs utilisations |
WO2021224850A1 (fr) | 2020-05-06 | 2021-11-11 | Crispr Therapeutics Ag | Peptides masques et anticorps anti-ptk7 masqués les comprenant |
EP4182346A1 (fr) | 2020-07-17 | 2023-05-24 | Pfizer Inc. | Anticorps thérapeutiques et leurs utilisations |
US20230287455A1 (en) | 2020-07-30 | 2023-09-14 | Pfizer Inc. | Cells Having Gene Duplications and Uses Thereof |
EP4229222A2 (fr) | 2020-10-19 | 2023-08-23 | Dana-Farber Cancer Institute, Inc. | Biomarqueurs germinaux de la réponse clinique et du bénéfice d'un traitement par inhibiteur de points de contrôle immunitaire |
WO2022104104A2 (fr) | 2020-11-13 | 2022-05-19 | Dana-Farber Cancer Institute, Inc. | Vaccins à cellules de fusion personnalisés |
US20220180972A1 (en) | 2020-12-04 | 2022-06-09 | Bostongene Corporation | Hierarchical machine learning techniques for identifying molecular categories from expression data |
WO2022159793A2 (fr) | 2021-01-25 | 2022-07-28 | Dana-Farber Cancer Institute, Inc. | Procédés et compositions pour identifier un cancer de la prostate neuroendocrinien |
WO2022232615A1 (fr) | 2021-04-29 | 2022-11-03 | Bostongene Corporation | Techniques d'apprentissage machine pour estimer une expression de cellules tumorales dans un tissu tumoral complexe |
WO2022261183A2 (fr) | 2021-06-08 | 2022-12-15 | Dana-Farber Cancer Institute, Inc. | Compositions et procédés de traitement et/ou d'identification d'un agent pour le traitement de cancers intestinaux |
WO2023012627A1 (fr) | 2021-08-02 | 2023-02-09 | Pfizer Inc. | Vecteurs d'expression améliorés et leurs utilisations |
CA3232833A1 (fr) | 2021-09-27 | 2023-03-30 | Kathleen Mcginness | Polypeptides recepteurs chimeriques en combinaison avec des molecules de metabolisme trans qui reorientent des metabolites de glucose hors de la voie de glycolyse et leurs utilisations therapeutique |
WO2023091909A1 (fr) | 2021-11-16 | 2023-05-25 | Sotio Biotech Inc. | Traitement de patients atteints de liposarcome myxoïde/à cellules rondes |
WO2023097119A2 (fr) | 2021-11-29 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Méthodes et compositions pour moduler riok2 |
WO2023147177A1 (fr) | 2022-01-31 | 2023-08-03 | Bostongene Corporation | Techniques d'apprentissage automatique pour cytométrie |
WO2023148598A1 (fr) | 2022-02-02 | 2023-08-10 | Pfizer Inc. | Prototrophie cystéinique |
WO2023158732A1 (fr) | 2022-02-16 | 2023-08-24 | Dana-Farber Cancer Institute, Inc. | Procédés de diminution de l'alpha-synucléine pathologique à l'aide d'agents qui modulent fndc5 ou des fragments biologiquement actifs de celui-ci |
WO2024015561A1 (fr) | 2022-07-15 | 2024-01-18 | Bostongene Corporation | Techniques de détection d'une déficience de recombinaison homologue (hrd) |
WO2024040207A1 (fr) | 2022-08-19 | 2024-02-22 | Sotio Biotech Inc. | Cellules tueuses naturelles (nk) génétiquement modifiées avec des polypeptides récepteurs chimériques en combinaison avec des molécules de trans-métabolisme et leurs utilisations thérapeutiques |
WO2024040208A1 (fr) | 2022-08-19 | 2024-02-22 | Sotio Biotech Inc. | Cellules immunitaires génétiquement modifiées avec des polypeptides récepteurs chimériques en combinaison avec de multiples molécules du métabolisme trans et leurs utilisations thérapeutiques |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993000103A1 (fr) * | 1991-06-21 | 1993-01-07 | The Wistar Institute Of Anatomy And Biology | Proteines d'enveloppe chimeriques pour le ciblage de virus |
WO1993022433A2 (fr) * | 1992-04-28 | 1993-11-11 | Frank Andreas Harald Meyer | Medicament permettant de traiter l'homme, les animaux et les plantes par therapie genetique, dans le but notamment de bloquer la proliferation de virus et les carcinogenes et procede de fabrication dudit medicament |
-
1993
- 1993-06-03 WO PCT/US1993/005260 patent/WO1993025234A1/fr not_active Application Discontinuation
- 1993-06-03 EP EP93914334A patent/EP0650370A4/fr not_active Withdrawn
- 1993-06-03 JP JP6501565A patent/JPH07507689A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993000103A1 (fr) * | 1991-06-21 | 1993-01-07 | The Wistar Institute Of Anatomy And Biology | Proteines d'enveloppe chimeriques pour le ciblage de virus |
WO1993022433A2 (fr) * | 1992-04-28 | 1993-11-11 | Frank Andreas Harald Meyer | Medicament permettant de traiter l'homme, les animaux et les plantes par therapie genetique, dans le but notamment de bloquer la proliferation de virus et les carcinogenes et procede de fabrication dudit medicament |
Non-Patent Citations (8)
Title |
---|
ADV. EXP. MED. BIOL. (1988), 241(MOL. BIOL. HEMOPOIESIS), 19-27 CODEN: AEMBAP;ISSN: 0065-2598 * |
CHEMICAL ABSTRACTS, vol. 111, no. 13, 25 September 1989, Columbus, Ohio, US; abstract no. 110248, EGLITIS, MARTIN A. ET AL: "Retroviral-mediated gene transfer into hemopoietic cells" * |
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; * |
KASAHARA N. ET AL.: "TARGETED GENE DELIVERY BY RETROVIRUSES WITH PEPTIDE HORMONE SEQUENCES INCORPORATED INTO THE ENVELOPE.", J. CELL BIOCHEM. SUPPL., vol. 0, pages 237 * |
LI, JING PO ET AL: "Activation of cell growth by binding of Friend spleen focus-forming virus gp55 glycoprotein to the erythropoietin receptor", NATURE (LONDON) (1990), 343(6260), 762-4 CODEN: NATUAS;ISSN: 0028-0836 * |
RANDY A. HOCK ET AL.: "RETROVIRUS-MEDIATED TRANSFER AND EXPRESSION OF DRUG RESISTANCE GENES IN HUMAN HAEMATOPOIETIC PROGENITOR CELLS.", NATURE, vol. 320, 20 March 1986 (1986-03-20), LONDON GB, pages 275 - 277 * |
See also references of WO9325234A1 * |
YOSHIMURA, AKIHIKO ET AL: "Friend spleen focus-forming virus glycoprotein gp55 interacts with the erythropoietin receptor in the endoplasmic reticulum and affects receptor metabolism", PROC. NATL. ACAD. SCI. U. S. A. (1990), 87(11), 4139-43 CODEN: PNASA6;ISSN: 0027-8424 * |
Also Published As
Publication number | Publication date |
---|---|
EP0650370A1 (fr) | 1995-05-03 |
WO1993025234A1 (fr) | 1993-12-23 |
JPH07507689A (ja) | 1995-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0650370A4 (fr) | Procedes et compositions permettant de cibler des tissus specifiques. | |
PH31081A (en) | Methods and compositions for mineralizing and fluoridating calcified tissues. | |
EP0634459A3 (fr) | Formulations. | |
ZA932646B (en) | Cosmetic composition. | |
ZA936704B (en) | Cosmetic composition. | |
ZA945653B (en) | Therapeutic compositions | |
EP0640097A4 (fr) | Compositions et procedes de vaccination contre les coronavirus. | |
EP0604748A3 (fr) | Manchon de trocart. | |
ZA932586B (en) | Cosmetic composition. | |
GB2271059B (en) | Pharmaceutical compositions comprising aconitane derivatives and tetrahydroprotoberberine derivatives. | |
ZA942814B (en) | Agricultural formulations | |
EP0596962A4 (en) | Therapeutic compositions and methods. | |
PH31211A (en) | Cosmetic composition. | |
EP0656791A4 (fr) | Compositions et methodes therapeutiques a base de 2,7,9-tricarboxy-pyrroloquinoleine (pqq). | |
HK1001286A1 (en) | Benzopyrans and their use as therapeutic agents. | |
ZA966063B (en) | Synergistic herbicidal composition and method of use thereof. | |
GB2294213B (en) | Pulverizer | |
AU3674595A (en) | Antianemic agent containing iron and difructose | |
AU663832B2 (en) | Easy chess-like game | |
EP0586848A3 (fr) | Implant. | |
EP0673640A4 (fr) | Composition de traitement intermediaire pour la permanente. | |
EP0868430A4 (fr) | Compositions therapeutiques | |
AU3423397A (en) | Therapeutic methods and compositions for use therein | |
ZA93662B (en) | Sterilising composition | |
PL303352A1 (en) | Symmetrical plough |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19941124 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19951006 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
RHK1 | Main classification (correction) |
Ipc: A61K 39/12 |
|
17Q | First examination report despatched |
Effective date: 19980605 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19991125 |